LeonaBio (LONA) Liabilities and Shareholders Equity (2019 - 2026)

LeonaBio (LONA) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $71.6 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 64.53% year-over-year to $71.6 million in Q1 2026; TTM through Mar 2026 was $229.3 million, a 23.51% decrease from a year earlier, with the FY2025 full-year figure at $92.2 million, up 56.78% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $71.6 million, down from $92.2 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for LONA reached as high as $313.0 million in Q1 2022 and fell as low as $30.0 million in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $152.1 million across 5 years, with a median of $133.5 million in 2024.
• Across the five-year window, Liabilities and Shareholders Equity slumped 68.05% in 2025 and jumped 64.53% in 2026, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $258.2 million in 2022, then slumped by 37.93% to $160.2 million in 2023, then sank by 63.32% to $58.8 million in 2024, then soared by 56.78% to $92.2 million in 2025, then retreated by 22.31% to $71.6 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $71.6 million in Q1 2026, $92.2 million in Q4 2025, and $30.0 million in Q3 2025.